Atractylenolide I

Name: Atractylenolide I
Brand: MedChemExpress
SKU: HY-N0201
Rating: 5.0 (2 reviews)

Cat. No.: HY-N0201 Purity: 99.94%: FAQs
Data Sheet SDS COA Handling Instructions

Molarity Calculator

Atractylenolide I is a sesquiterpene derived from the rhizome of Atractylodes macrocephala, possesses diverse bioactivities, such as neuroprotective, anti-allergic, anti-inflammatory and anticancer properties. Atractylenolide I reduces protein levels of phosphorylated JAK2 and STAT3 in A375 cells, and acts as a TLR4-antagonizing agent.

For research use only. We do not sell to patients.

Atractylenolide I Chemical Structure

CAS No. : 73069-13-3

Size	Price	Stock	Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	USD 119	In-stock	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	USD 119	In-stock	Estimated Time of Arrival: December 31
Solid
1 mg	USD 47	In-stock	Estimated Time of Arrival: December 31
5 mg	USD 99	In-stock	Estimated Time of Arrival: December 31
10 mg	USD 165	In-stock	Estimated Time of Arrival: December 31
50 mg	USD 539	In-stock	Estimated Time of Arrival: December 31
100 mg		Get quote
200 mg		Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 2 publication(s) in Google Scholar

Other Forms of Atractylenolide I:

Atractylenolide I (Standard) Get quote

2 Publications Citing Use of MCE Atractylenolide I

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All TNF Receptor Isoform Specific Products:

View All Isoforms

TNFRSF1A/CD120a TNFRSF5/CD40 TNFRSF6/Fas/CD95 TNFRSF8/CD30 TNFRSF9/4-1BB/CD137 TNFRSF16/NGF Receptor/CD271 TNFRSF18/GITR/CD357

View All Toll-like Receptor (TLR) Isoform Specific Products:

View All Isoforms

TLR3 TLR8 TLR9 TLR2 TLR4 TLR7 TLR1 TLR6

View All JAK Isoform Specific Products:

View All Isoforms

JAK1 JAK2 JAK3 Tyk2 JAK

View All STAT Isoform Specific Products:

View All Isoforms

STAT3 STAT5 STAT6 STAT1

Biological Activity
Protocol
Purity & Documentation
References
Customer Review

Description

IC₅₀ & Target

TLR7

TLR9

Cellular Effect

Cell Line	Type	Value	Description	References
Jurkat	IC₅₀	24.44 μg/mL Compound: ATL-1	Cytotoxicity against human Jurkat T cells assessed as growth inhibition after 48 hrs by MTT assay Cytotoxicity against human Jurkat T cells assessed as growth inhibition after 48 hrs by MTT assay	[PMID: 26988300]
Jurkat	IC₅₀	37.63 μg/mL Compound: ATL-1	Cytotoxicity against human Jurkat T cells assessed as growth inhibition after 24 hrs by MTT assay Cytotoxicity against human Jurkat T cells assessed as growth inhibition after 24 hrs by MTT assay	[PMID: 26988300]
Jurkat	IC₅₀	44.67 μg/mL Compound: ATL-1	Cytotoxicity against human Jurkat T cells assessed as growth inhibition after 12 hrs by MTT assay Cytotoxicity against human Jurkat T cells assessed as growth inhibition after 12 hrs by MTT assay	[PMID: 26988300]
U-937	IC₅₀	14.91 μg/mL Compound: ATL-1	Cytotoxicity against human U937 cells assessed as growth inhibition after 24 hrs by MTT assay Cytotoxicity against human U937 cells assessed as growth inhibition after 24 hrs by MTT assay	[PMID: 26988300]
U-937	IC₅₀	24.11 μg/mL Compound: ATL-1	Cytotoxicity against human U937 cells assessed as growth inhibition after 12 hrs by MTT assay Cytotoxicity against human U937 cells assessed as growth inhibition after 12 hrs by MTT assay	[PMID: 26988300]
U-937	IC₅₀	4.23 μg/mL Compound: ATL-1	Cytotoxicity against human U937 cells assessed as growth inhibition after 48 hrs by MTT assay Cytotoxicity against human U937 cells assessed as growth inhibition after 48 hrs by MTT assay	[PMID: 26988300]

In Vitro

Atractylenolide I (40, 60, 80, 100, 120, 150 μM) dose- and time-dependently reduces the cell viability in human A375 melanoma cells after treatment for 24, 48 and 72 hours. Atractylenolide I (50 and 100 μM) induces apoptosis of A375 cells in a dose-dependent manner at 48 h of treatment. Atractylenolide I (100 μM) significantly reduces protein levels of phosphorylated JAK2 and STAT3 in A375 cells, without effect on total JAK2 and STAT3. Furthermore, Atractylenolide I inhibits the mRNA expression of STAT3-targeted genes, including Bcl-xL, MMP-2 and MMP-9^[1]. Atractylenolide I (up to 100 μM) shows no toxicity in normal cells. Atractylenolide I (25, 50 μM) decreases the Ox-LDL induced TNF-α, IL-6 and NO production in VSMCs. Atractylenolide I (12.5, 25 or 50 μM) significantly reduces the level of MCP-1 and inhibits Ox-LDL-induced VSMCs proliferation and migration. Atractylenolide I (25, 50 μM) inhibits positive staining of foam cells, and also significantly decreases lipid accumulation. Atractylenolide I (50 μM) suppresses p38MAPK and NF-κB p65 expression in VSMCs stimulated by Ox-LDL^[3]. Atractylenolide I (1, 10, 100 μM) downregulates paclitaxel-induced expression of VEGF and survivin via MyD88-dependent TLR4 signaling in EOC cells^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Atractylenolide I (5, 10 or 20 mg/kg, p.o.) restores the decreased body weight in mice subjected to chronic unpredictable mild stress (CUMS). Atractylenolide I alleviates CUMS-induced depressive-like behavior, attenuates CUMS-induced imbalances in hippocampal neurotransmitter levels and reduces CUMS-induced increases in hippocampal pro-inflammatory cytokine levels and in the NLRP3 inflammasome in the hippocampi of mice^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Molecular Weight

230.30

Formula

C₁₅H₁₈O₂

CAS No.

73069-13-3

Appearance

Solid

Color

White to light yellow

SMILES

O=C1C(C)=C(C[C@@]23[H])C(O1)=C[C@@]3(C)CCCC2=C

Structure Classification

Initial Source

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Solvent & Solubility

In Vitro:

DMSO : 100 mg/mL (434.22 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	4.3422 mL	21.7108 mL	43.4216 mL
5 mM	0.8684 mL	4.3422 mL	8.6843 mL
10 mM	0.4342 mL	2.1711 mL	4.3422 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (10.86 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (10.86 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.5 mg/mL (10.86 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Purity & Documentation

Purity: 99.94%

Select Batch:

Data Sheet (281 KB) SDS (251 KB)

COA (250 KB) HNMR (246 KB) LCMS (85 KB)

Handling Instructions (2659 KB)

References

[1]. Atractylenolide I, et al. The JAK2/STAT3 pathway is involved in the anti-melanoma effects of atractylenolide I. Exp Dermatol. 2018 Feb;27(2):201-204. [Content Brief]

[2]. Gao H, et al. Anti-depressant-like effect of atractylenolide I in a mouse model of depression induced by chronic unpredictable mild stress. Exp Ther Med. 2018 Feb;15(2):1574-1579. [Content Brief]

[3]. Li W, et al. Atractylenolide I restores HO-1 expression and inhibits Ox-LDL-induced VSMCs proliferation, migration and inflammatory responses in vitro. Exp Cell Res. 2017 Apr 1;353(1):26-34. [Content Brief]

[4]. Huang JM, et al. Atractylenolide-I sensitizes human ovarian cancer cells to paclitaxel by blocking activation of TLR4/MyD88-dependent pathway. Sci Rep. 2014 Jan 23;4:3840. [Content Brief]

Cell Assay ^[3]	Briefly, serum starved VSMCs are pre-treated with indicated concentration of Atractylenolide I for 1 h followed by stimulation with Ox-LDL for 24 h. The purple formazan crystals formed after addition of MTT are solubilized in DMSO and absorbance is measured at 540 nm. The viability or proliferation rate is calculated as percentage of control (untreated VSMCs)^[3]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Administration ^[2]	Mice^[2] After adaption for one week, 48 male ICR mice are randomly divided into six groups (eight mice per group): Control group (unstressed + saline vehicle), model group (CUMS + saline vehicle), three Atractylenolide I treatment groups (CUMS + Atractylenolide I) and a fluoxetine group (CUMS + FLU). From the 4th week, Atractylenolide I (5, 10 or 20 mg/kg) or fluoxetine (20 mg/kg) is daily administered by oral gavage for 3 weeks. After the last administration of Atractylenolide I or fluoxetine, behavioral tests are performed^[2]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
References	[1]. Atractylenolide I, et al. The JAK2/STAT3 pathway is involved in the anti-melanoma effects of atractylenolide I. Exp Dermatol. 2018 Feb;27(2):201-204. [Content Brief] [2]. Gao H, et al. Anti-depressant-like effect of atractylenolide I in a mouse model of depression induced by chronic unpredictable mild stress. Exp Ther Med. 2018 Feb;15(2):1574-1579. [Content Brief] [3]. Li W, et al. Atractylenolide I restores HO-1 expression and inhibits Ox-LDL-induced VSMCs proliferation, migration and inflammatory responses in vitro. Exp Cell Res. 2017 Apr 1;353(1):26-34. [Content Brief] [4]. Huang JM, et al. Atractylenolide-I sensitizes human ovarian cancer cells to paclitaxel by blocking activation of TLR4/MyD88-dependent pathway. Sci Rep. 2014 Jan 23;4:3840. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	4.3422 mL	21.7108 mL	43.4216 mL	108.5541 mL
	5 mM	0.8684 mL	4.3422 mL	8.6843 mL	21.7108 mL
	10 mM	0.4342 mL	2.1711 mL	4.3422 mL	10.8554 mL
	15 mM	0.2895 mL	1.4474 mL	2.8948 mL	7.2369 mL
	20 mM	0.2171 mL	1.0855 mL	2.1711 mL	5.4277 mL
	25 mM	0.1737 mL	0.8684 mL	1.7369 mL	4.3422 mL
	30 mM	0.1447 mL	0.7237 mL	1.4474 mL	3.6185 mL
	40 mM	0.1086 mL	0.5428 mL	1.0855 mL	2.7139 mL
	50 mM	0.0868 mL	0.4342 mL	0.8684 mL	2.1711 mL
	60 mM	0.0724 mL	0.3618 mL	0.7237 mL	1.8092 mL
	80 mM	0.0543 mL	0.2714 mL	0.5428 mL	1.3569 mL
	100 mM	0.0434 mL	0.2171 mL	0.4342 mL	1.0855 mL